HK1203832A1 - Oral pharmaceutical compositions of dabigatran etexilate - Google Patents

Oral pharmaceutical compositions of dabigatran etexilate

Info

Publication number
HK1203832A1
HK1203832A1 HK15104458.0A HK15104458A HK1203832A1 HK 1203832 A1 HK1203832 A1 HK 1203832A1 HK 15104458 A HK15104458 A HK 15104458A HK 1203832 A1 HK1203832 A1 HK 1203832A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
oral pharmaceutical
dabigatran etexilate
etexilate
dabigatran
Prior art date
Application number
HK15104458.0A
Other languages
English (en)
Chinese (zh)
Inventor
Pratibha S Pilgaonkar
Maharukh T Rustomjee
Anilkumar S Gandhi
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47739283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1203832(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of HK1203832A1 publication Critical patent/HK1203832A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15104458.0A 2012-02-21 2015-05-12 Oral pharmaceutical compositions of dabigatran etexilate HK1203832A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN461MU2012 2012-02-21
PCT/EP2013/053426 WO2013124340A1 (en) 2012-02-21 2013-02-21 Oral pharmaceutical compositions of dabigatran etexilate

Publications (1)

Publication Number Publication Date
HK1203832A1 true HK1203832A1 (en) 2015-11-06

Family

ID=47739283

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104458.0A HK1203832A1 (en) 2012-02-21 2015-05-12 Oral pharmaceutical compositions of dabigatran etexilate

Country Status (27)

Country Link
US (3) US11013729B2 (xx)
EP (2) EP2817000B1 (xx)
JP (1) JP6215239B2 (xx)
KR (1) KR102090242B1 (xx)
CN (2) CN110123774A (xx)
AU (1) AU2013224146B2 (xx)
BR (1) BR112014020474B1 (xx)
CA (1) CA2864423C (xx)
CY (1) CY1124678T1 (xx)
DK (1) DK2817000T3 (xx)
ES (1) ES2895918T3 (xx)
HK (1) HK1203832A1 (xx)
HR (1) HRP20211606T1 (xx)
HU (1) HUE056194T2 (xx)
IL (1) IL234032B (xx)
IN (1) IN2014DN06734A (xx)
JO (1) JO3616B1 (xx)
LT (1) LT2817000T (xx)
MX (1) MX368868B (xx)
NZ (1) NZ628301A (xx)
PL (1) PL2817000T3 (xx)
PT (1) PT2817000T (xx)
RS (1) RS62566B1 (xx)
RU (1) RU2633482C2 (xx)
SI (1) SI2817000T1 (xx)
WO (1) WO2013124340A1 (xx)
ZA (1) ZA201405855B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2817000B1 (en) 2012-02-21 2021-08-04 Towa Pharmaceutical Europe, S.L. Oral pharmaceutical compositions of dabigatran etexilate
CN104224754A (zh) * 2013-06-21 2014-12-24 四川海思科制药有限公司 一种达比加群酯药物组合物及其制备方法
CN104414995A (zh) * 2013-09-04 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯的药用组合物
EP2853260A1 (en) * 2013-09-27 2015-04-01 ratiopharm GmbH Pharmaceutical preparation comprising dabigatran etexilate bismesylate
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN104784147B (zh) * 2014-01-20 2018-01-23 成都苑东生物制药股份有限公司 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法
CN104994856A (zh) * 2014-01-30 2015-10-21 杭州领业医药科技有限公司 达比加群酯及其盐的投药制剂及其制备方法
CN104922092A (zh) * 2014-03-19 2015-09-23 陕西天森药物研究开发有限公司 一种通过包裹法制备的达比加群酯或其盐和水合物的药物组合
IN2014MU01042A (xx) 2014-03-26 2015-10-02 Cadila Healthcare Ltd
CN104095830A (zh) * 2014-05-22 2014-10-15 万特制药(海南)有限公司 一种甲磺酸盐达比加群酯胶囊的制备方法
CN104825422B (zh) * 2014-09-29 2017-12-12 普济生物科技（台州）有限公司 含达比加群酯甲磺酸盐的药物组合物及其制备方法
CN105560206A (zh) * 2014-10-13 2016-05-11 重庆圣华曦药业股份有限公司 一种达比加群酯胶囊的制备
CA3001495C (en) * 2014-11-03 2021-07-20 Solipharma Llc Formulations of dabigatran etexilate or dabigatran etexilate salts and preparation methods thereof
WO2016107605A1 (zh) * 2014-12-31 2016-07-07 昆明积大制药股份有限公司 药物组合物及其制备方法
WO2017103945A1 (en) * 2015-12-15 2017-06-22 Strides Shasun Limited Pharmaceutical compositions
CN106890148A (zh) * 2015-12-21 2017-06-27 青岛黄海制药有限责任公司 一种达比加群酯片剂及其制备
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
JP2018184375A (ja) * 2017-04-27 2018-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法
WO2019004980A2 (en) * 2017-05-10 2019-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE
TR201706848A2 (tr) * 2017-05-10 2018-11-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
TR201722353A2 (tr) * 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatran eteksi̇lat i̇çeren oral uygulama i̇çi̇n farmasöti̇k formülasyon
TR201722323A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722630A2 (xx) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
CN110339193B (zh) 2018-04-04 2022-04-29 上海汉都医药科技有限公司 含达比加群酯的药物组合物及其制备方法
EP3787624A4 (en) 2018-05-04 2022-03-30 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi DABIGATRAN ETEXILATE CAPSULE IN CAPSULE COMPOSITIONS
TR201905308A2 (tr) * 2019-04-09 2020-10-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A capsule formulation of dabigatran etexilate
CN113577067B (zh) * 2021-06-03 2023-08-15 北京福元医药股份有限公司 一种甲磺酸达比加群酯药物制剂
CN115006363A (zh) * 2022-06-23 2022-09-06 上海信谊万象药业股份有限公司 一种牡蛎碳酸钙咀嚼片及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
JPH04103525A (ja) 1990-08-22 1992-04-06 Sanwa Kagaku Kenkyusho Co Ltd 難水溶性薬物の持続性製剤化方法
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
TW550090B (en) 1997-05-09 2003-09-01 Sage Pharmaceuticals Inc Stable oral pharmaceutical dosage forms for acid-unstable drug
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DE60236850D1 (de) 2001-02-15 2010-08-12 Mitsubishi Tanabe Pharma Corp Tabletten, die in der mundhöhle schnell zerfallen
DE10209985A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze
JP3866715B2 (ja) * 2002-03-07 2007-01-10 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステル及びその塩の経口適用の投与形態
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
AU2004289222B2 (en) 2003-11-04 2010-01-21 Supernus Pharmaceuticals Inc. Compositions of quaternary ammonium containing bioavailability enhancers
CN1976903A (zh) 2004-06-02 2007-06-06 法莫西克立克斯公司 因子VⅡa抑制剂
KR101257343B1 (ko) 2004-07-30 2013-04-23 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제
AU2006337643A1 (en) 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Dipyridamole extended-release formulations and process for preparing same
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
EP2271317B1 (de) 2008-03-28 2017-04-19 Boehringer Ingelheim International GmbH Verfahren zur herstellung von säurepellets
CN101980697A (zh) * 2008-03-28 2011-02-23 贝林格尔.英格海姆国际有限公司 制备口服给药的达比加群制剂的方法
NZ589746A (en) * 2008-07-14 2012-10-26 Boehringer Ingelheim Int Method for manufacturing medicinal compounds containing dabigatran
EP2588090B2 (en) * 2010-07-01 2023-11-22 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
EA201391758A1 (ru) 2011-05-24 2014-06-30 Тева Фармасьютикал Индастриз Лтд. Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты
EP2817000B1 (en) 2012-02-21 2021-08-04 Towa Pharmaceutical Europe, S.L. Oral pharmaceutical compositions of dabigatran etexilate
CN102793699B (zh) 2012-08-06 2014-06-04 严轶东 一种含有达比加群酯的药用组合物

Also Published As

Publication number Publication date
SI2817000T1 (sl) 2022-02-28
RS62566B1 (sr) 2021-12-31
DK2817000T3 (da) 2021-10-11
MX368868B (es) 2019-10-11
IL234032A0 (en) 2014-09-30
CY1124678T1 (el) 2022-07-22
BR112014020474B1 (pt) 2022-03-29
CA2864423A1 (en) 2013-08-29
AU2013224146A1 (en) 2014-08-28
BR112014020474A2 (pt) 2020-02-11
CN110123774A (zh) 2019-08-16
EP2817000B1 (en) 2021-08-04
CN104114158A (zh) 2014-10-22
NZ628301A (en) 2015-07-31
US20210244719A1 (en) 2021-08-12
EP2817000A1 (en) 2014-12-31
US20150030680A1 (en) 2015-01-29
PL2817000T3 (pl) 2022-03-28
LT2817000T (lt) 2021-11-10
MX2014010040A (es) 2014-11-10
PT2817000T (pt) 2021-11-02
KR20140135216A (ko) 2014-11-25
JP6215239B2 (ja) 2017-10-18
EP3858337A2 (en) 2021-08-04
JO3616B1 (ar) 2020-08-27
RU2633482C2 (ru) 2017-10-12
US11013729B2 (en) 2021-05-25
HUE056194T2 (hu) 2022-01-28
RU2014138036A (ru) 2016-04-20
EP3858337A3 (en) 2021-09-29
KR102090242B1 (ko) 2020-03-18
ZA201405855B (en) 2015-11-25
ES2895918T3 (es) 2022-02-23
AU2013224146B2 (en) 2017-06-08
IL234032B (en) 2020-06-30
US20240139168A1 (en) 2024-05-02
IN2014DN06734A (xx) 2015-05-22
WO2013124340A1 (en) 2013-08-29
HRP20211606T1 (hr) 2022-01-21
JP2015511241A (ja) 2015-04-16
US11752142B2 (en) 2023-09-12
CA2864423C (en) 2021-08-10

Similar Documents

Publication Publication Date Title
HK1203832A1 (en) Oral pharmaceutical compositions of dabigatran etexilate
EP2661273A4 (en) IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
HUE056143T2 (hu) Pimobendán javított gyógyászati készítményei
HK1215379A1 (zh) 過氧化物穩定的口腔護理組合物
IL221742A (en) Oral Pharmaceuticals Containing Debigtran Etxylate
HK1199821A1 (en) Oral pharmaceutical composition
HRP20180567T1 (hr) Farmaceutski pripravak omeprazola
ZA201503649B (en) Peroxide-stable oral care compositions
HK1199822A1 (zh) 口服給藥用醫藥組合物
IL234099A0 (en) Solid forms of dabigatran etexilate mesylate and processes for their preparation
HK1214160A1 (zh) 抑制劑的藥物組合物
PL2887924T3 (pl) Kompozycje farmaceutyczne etorykoksybu
PT3524260T (pt) Composições farmacêuticas para o tratamento de inapetência
HK1213785A1 (zh) 血管緊張素的口服製劑
EP2919749A4 (en) ORAL CARE COMPOSITIONS
EP3019159A4 (en) Oral pharmaceutical compositions comprising imatinib mesylate
HK1202451A1 (en) Therapeutic compositions for intranasal administration of zolpidem
SG11201404807PA (en) Oral care compositions